Fluphenazine (oral) versus placebo for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Matar, Hosam E ^a   Almerie, Muhammad Qutayba ^b   Sampson, Stephanie ^c  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE; PLACEBO; NEUROLEPTIC AGENT;

AKATHISIA; AKINESIA; AMENORRHEA; ANXIETY DISORDER; BLURRED VISION; CLINICAL OUTCOME; CONSTIPATION; CONVULSION; DEATH; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DYSTONIA; FAINTNESS; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSPITAL DISCHARGE; HUMAN; HYPERSALIVATION; HYPOTENSION; INFECTION; INSOMNIA; LETHARGY; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NOSE OBSTRUCTION; PARKINSONISM; PRIORITY JOURNAL; PRODROME STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; RESTLESSNESS; REVIEW; RISK; SCHIZOPHRENIA; SEIZURE; SYSTEMATIC REVIEW; TACHYCARDIA; TREMOR; URINARY DYSFUNCTION; VOMITING; WEAKNESS; XEROSTOMIA; META ANALYSIS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; FLUPHENAZINE; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84891639321     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006352.pub2     Document Type: Review

References (130)

1. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Breier AF. Diazepam treatment of early signs of exacerbation in schizophrenia. American Journal of Psychiatry 1999;156(2):299-303. [MEDLINE: 99178642]
2. Clark ML, Huber WK, Charalampous KD, Serafetinides EA, Trousdale W, Colmore JP. Drug treatment in newly admitted schizophrenic patients. Archives of General Psychiatry 1971;25(5):404-9. [MEDLINE: 72081786]
3. Cole JO, Goldberg SC, Klerman GL. Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry 1964;10:246-61. [MEDLINE: 71204770]
4. Gibbons RD, Lewine RRJ, Davis JM, Schooler NR, Cole JO. An empirical test of a kraepelinian vs. a bleulerian view of negative symptoms. Schizophrenia Bulletin 1985;11(3):390-5. [MEDLINE: 71204770]
5. Goldberg SC, Klerman GL, Cole JO. Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment. British Journal of Psychiatry 1965;111:120-33. [MEDLINE: 5677325]
6. Goldberg SC, Mattsson N, Cole JO, Klerman GL. Prediction of improvement in schizophrenia under four phenothiazines. Archives of General Psychiatry 1967;16:107-17. [MEDLINE: 6066689]
7. Goldberg SC, Mattsson NB. Schizophrenic subtypes defined by response to drugs and placebo. Diseases of the Nervous System 1968;29(5):S153-8. [MEDLINE: 68399894]
8. Klerman GL, Goldberg SG, Davis D. Relationship between the hospital milieu and the response to phenothiazines in the treatment of schizophrenics. Acta Psychiatrica Belgica 1970;70(6):716-29. [MEDLINE: 71204770]
9. Hordern A, King A, Holt NF, Collins J, Toussaint J. Thioproperazine in chronic schizophrenia. British Journal of Psychiatry 1964;110:531-9. [MEDLINE: 79181666]
10. Marder SR, Wirshing WC, van Putten T, Mintz J, McKenzie J, Johnston-Cronk K, et al. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia. Archives of General Psychiatry 1994;51(4):280-7. [MEDLINE: 94213575]
11. Millar J. A trial of fluphenazine in schizophrenia. British Journal of Psychiatry 1963;109:428-32. [MEDLINE: 769023]
12. Rifkin A, Quitkin F, Kane J, Klein DF. Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data. Psychopharmacology Bulletin 1977;13(2):40-50. [MEDLINE: 323910]
13. Rifkin A, Quitkin F, Kane J, Klein DF, Ross D. The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics. Biological Psychiatry 1979;14(3):499-508. [MEDLINE: 224958;: PsycINFO 64-08562]
14. Rifkin A, Quitkin F, Klein DF. Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data. Archives of General Psychiatry 1977;34(10):15-9. [MEDLINE: 78019044]
15. Rifkin A, Quitkin F, Rabiner CJ, Klein DF. Comparison of fluphenazine decanoate, oral fluphenazine, and placebo in remitted outpatient schizophrenics. Psychopharmacology Bulletin 1976;12(2):24-6. [MEDLINE: 769022]
16. Rifkin A, Quitkin F, Rabiner CJ, Klein DF. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Archives of General Psychiatry 1977;34(1):43-7. [MEDLINE: 77111134]
17. Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R. Vitamin E treatment for tardive dyskinesia. Archives of General Psychiatry 1999;56(9):836-41. [: EMBASE 1999313441]
18. Adler LA, Rotrosen J, Lavori P, Edson R. Vitamin E treatment of TD: development of a VA cooperative study. Biological Psychiatry 1994;35:730-1. [MEDLINE: 11760]
19. Caligiuri MP, Lohr JB, Rotrosen J, Adler L, Lavori P, Edson R, et al. Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study 394. Psychopharmacology 1997;132(1):61-6. [: EMBASE 1997216311]
20. Baldini JT, Neary ER. Controlled trials of an amitriptyline-fluphenazine combination in depressive neuroses and psychoses: a collaborative study. Current Therapeutic Research, Clinical and Experimental 1970;12(2):84-93. [MEDLINE: 70113586]
21. Boyer P, Lecrubier Y, Puech AJ. Treatment of positive and negative symptoms: pharmacologic approaches. Modern Problems of Pharmacopsychiatry 1990;24:152-74. [MEDLINE: 11782241]
22. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry 1995;166(1):68-72. [MEDLINE: 7894879]
23. Boyer P, Puech AJ. Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools [Modalities d'action clinique des neuroleptiques: substances, doses, instruments de mesure utilises]. Psychiatrie and Psychobiologie 1987;2(4):296-305. [: PsycINFO 76-12830]
24. Boyer P, Puech AJ, Lecrubier Y. Double blind trial versus placebo of low dose amisulpride (Solian 50) in schizophrenia with exclusively negative symptoms. Preliminary analysis of results [Etude en double insu contre placebo de l'amisulpride (Solian (r) 50) a faible dose chez des schizophrenes purement deficitaires. Premiere analyse des resultats]. Annales de Psychiatrie 1988;3(3):321-5. [: EMBASE 1988242981]
25. Lecrubier Y. Amisulpride in deficit schizophrenia. 6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France. 1997. [MEDLINE: 7894879]
26. Rein W, Turjanski S. Clinical update on amisulpride in deficit schizophrenia. International Clinical Psychopharmacology 1997;12(Suppl 2):S19-27. [MEDLINE: 97361270]
27. Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW, et al. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. American Journal of Psychiatry 1987;144:1549-55. [MEDLINE: 3688278]
28. Carpenter WT, Buchanan RW, Breier A, Kirkpatrick B, Hanlon T, Levine J, et al. Novel neuroleptic dosage reduction strategies. Schizophrenia Research 1992;6(2):107. [MEDLINE: 3688278]
29. Chacon C, Harper P, Harvey GF. Work study in the assessment of the effects of phenothiazines in schizophrenia. Comprehensive Psychiatry 1972;13(6):549-54. [MEDLINE: 73051431;: PsycINFO 1973-31686-001]
30. Chacon C, Harper P. Clinical and work performance variables in phenothiazine therapy of schizophrenia. Acta Psychiatrica Scandinavica 1973;49(1):65-76. [MEDLINE: 4572169]
31. Coffman JA, Nasrallah HA, Lyskowski J, McCalley-Whitters M, Dunner FJ. Clinical effectiveness of oral and parenteral rapid neuroleptization. Journal of Clinical Psychiatry 1987;48(1):20-4. [: EMBASE 1987061089]
32. Del Giudice J, Clark WG, Gocka EF. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 1975;16(1):32-6. [MEDLINE: 76032528;: PsycINFO 54-12277]
33. Doran AR, Labarca R, Wolkowitz OM, Roy A, Douillet P, Pickar D. Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with Schizophrenia. Archives of General Psychiatry 1990;47:558-63. [MEDLINE: 2350208]
34. Downing RW, Ebert JN, Shubrooks SJ. Effect of phenothiazines on the thinking of acute schizophrenics. Perceptual and Motor Skills 1963;17(2):511-20. [: PsycINFO 1964-06498-001]
35. Elman I, Goldstein DS, Eisenhofer G, Folio J, Malhotra AK, Adler CM, et al. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropyschopharmacology 1999;20(1):29-34. [MEDLINE: 99103168]
36. Haider I. A controlled trial of fluphenazine enanthate in hospitalized chronic schizophrenics. British Journal of Psychiatry 1968;114(512):837-41. [MEDLINE: 4874164]
37. Hanlon TE, Ota KY, Kurland AA. Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine. Diseases of the Nervous System 1970;31(3):171-7. [MEDLINE: 4909632]
38. Held JM, Cromwell RL, Frank ET Jr, Fann WE. Effect of phenothiazines on reaction time in schizophrenics. Journal of Psychiatric Research 1970;7(3):209-13. [MEDLINE: 70166858]
39. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry 1979;36(12):1283-94. [MEDLINE: 80041623]
40. Holden JM, Itil TM, Keskiner A. Assessment and significance of changes in laboratory values with haloperidol and fluphenazine hydrochloride therapy. Biological Psychiatry 1970;2(2):173-82. [MEDLINE: 4918019]
41. Howell RJ, Brown HM, Beaghler HE. A comparison of fluphenazine, trifluoperazine and a placebo in the context of an active treatment unit. Journal of Nervous and Mental Disease 1961;132:522-30. [MEDLINE: 13716275]
42. Itil TM, Saletu B, Hsu W, Kiremitci N, Keskiner A. Clinical and quantitative EEG changes at different dosage levels of fluphenazine treatment. Acta Psychiatrica Scandinavica 1971;47(4):440-51. [MEDLINE: 4947806]
43. Itil TM, Marasa J, Saletu B, Davis S, Mucciardi AN. Computerized EEG: predictor of outcome in schizophrenia. Journal of Nervous and Mental Disease 1975;160(3):188-203. [MEDLINE: 75116033]
44. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Archives of General Psychiatry 1982;39(1):70-3. [MEDLINE: 82112452]
45. Kinross-Wright J, Vogt AH, Charalampous KD. A new method of drug therapy. American Journal of Psychiatry 1963;119:779-80. [MEDLINE: 14032917]
46. Kinross-Wright J, Charalampous KD. A controlled study of a very long-acting phenothiazine preparation. International Journal of Neuropsychiatry 1964;1:66-70. [: PsycINFO 60-03426]
47. Hirsch SR, Gaind R, Rohde PD, Stevens BC, Wing JK. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. British Medical Journal 1973;1(854):633-7. [MEDLINE: 4571196]
48. Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. British Medical Journal 1971;3(775):599-604. [MEDLINE: 71287275]
49. Litman RE, Hommer DW, Radant A, Clem T, Pickar D. Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia. Schizophrenia Research 1994;12(2):107-20. [MEDLINE: 94318574]
50. Marder SR, van Putten T, Aravagiri M, Hubbard JW, Hawes EM, McKay G, et al. Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine. Psychopharmacology Bulletin 1989;25(3):479-82. [MEDLINE: 2626520]
51. Marder SR, Wirshing WC, Eckman T. Psychosocial and pharmacological strategies for maintenance therapy: effects on two - year outcome. Schizophrenia Research 1993;9:260.
52. Martin IC. Implications of phenothiazine side effects: a study of antiparkinsonian agents in an older population. Acta Psychiatrica Scandinavica 1975;51(2):110-8. [MEDLINE: 235189]
53. Matheu H, Fogel EJ. Clinical effects of fluphenazine dihydrychloride in chronic schizophrenia. Journal of Neuropsychiatry 1961;3:105-11. [MEDLINE: 14471099]
54. Mattes JA, Nayak D. Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives. Biological Psychiatry 1984;19(3):445-9. [MEDLINE: 6722235;: PsycINFO 72-10290]
55. Boyer P, Lecrubier Y, Puech AJ. Treatment of positive and negative symptoms: pharmacologic approaches. Modern Problems of Pharmacopsychiatry 1990;24:152-74. [MEDLINE: 11782241]
56. Boyer P, Puech AJ. Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools [Modalities d'action clinique des neuroleptiques: substances, doses, instruments de mesure utilises]. Psychiatrie and Psychobiologie 1987;2(4):296-305. [: PsycINFO 76-12830]
57. Pichot P, Boyer P. A double blind, controlled, multicenter trial of low dose amisulpride (Solian(R) 50) versus low dose fluphenazine in the treatment of negative symptoms in chronic schizophrenia [Essai multicentrique controle, en double insu, amisulpride (solian(r) 50) contre fluphenazine a faibles doses dans le traitement du syndrome deficitaire des schizophrenies chroniques]. Annales de Psychiatrie 1988;3(3):312-20. [: EMBASE 1988242980]
58. Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnoila M, Paul SM. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Archives of General Psychiatry 1986;43(7):669-76. [MEDLINE: 3718170]
59. Pickar D, Owen RR, Litman RE, Hsiao JK, Su TP. Predictors of clozapine response in schizophrenia. Journal of Clinical Psychiatry 1994;55(Suppl B):129-32. [MEDLINE: 95050371]
60. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Archives of General Psychiatry 1992;49(5):345-53. [MEDLINE: 92264872]
61. Quitkin F, Rifkin A, Kane J, Ramos Lorenzi JR, Klein DF. Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics. Archives of General Psychiatry 1978;35(7):889-92. [MEDLINE: 78234523]
62. Sampath G, Shah A, Krska J, Soni SD. Neuroleptic discontinuation in the very stable schizophrenic patient - relapse rates and serum neuroleptic levels. Human Psychopharmacology 1992;7(4):255-64. [: EMBASE 1992364197]
63. Schlosberg A, Shadmi M. A comparative controlled study of two long-acting phenothiazines: pipotiazine palmitate and fluphenazine decanoate. Current Therapeutic Research 1978;23(5):642-54. [: PsycINFO 62-01680]
64. Gelenberg AJ, Doller JC, Schooler NR, Mieske M, Severe J, Mandel MR. Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate. American Journal of Psychiatry 1979;136:217-9. [MEDLINE: 79101484]
65. Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. Advances in Biochemical Psychopharmacology 1980;24:483-93. [MEDLINE: 80262441]
66. Mandel MR, Severe JB, Schooler NR, Gelenberg AJ, Mieske M. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. Archives of General Psychiatry 1982;39(2):197-203. [MEDLINE: 82159410]
67. Schooler NR, Levine J. Dosage and side effect comparisons between oral and depot fluphenazine. Psychopharmacology Bulletin 1977;13(3):29-31. [MEDLINE: 329328]
68. Schooler NR, Levine J, +NIMH-PRB Collaborative Fluphenazine Study Group. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. Pharmacopsychiatry 1976;9(4):159-69. [MEDLINE: 77036977]
69. Schooler NR, Levine J, Severe JB. Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen. Psychopharmacology Bulletin 1979;15(2):44-7. [MEDLINE: 373006]
70. Schooler NR, Levine J, Severe JB, Brauzer B, DiMascio A, Klerman GL, et al. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Archives of General Psychiatry 1980;37(1):16-24. [MEDLINE: 80108511]
71. Shafti SS. Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia. Clinical Schizophrenia and Related Psychoses 2009;3(2):97-102.
72. Shenoy RS, Sadler AG, Goldberg SC, Hamer RM, Ross B. Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Journal of Clinical Psychopharmacology 1981;1(3):141-5. [MEDLINE: 82053610]
73. Steingard S, Allen M, Schooler NR. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse. Journal of Clinical Psychiatry 1994;55(11):470-2.
74. Stevens B. The social value of fluphenazine decanoate. Acta Psychiatrica Belgica 1976;76(5):792-804. [MEDLINE: 77178598]
75. Turner P. A comparison of fluphenazine and chlorpromazine on critical flicker fusion frequency. Journal of Pharmacy and Pharmacology 1966;18:836. [MEDLINE: 67163670]
76. van Praag HM, Breetveld J, van Mesdag Etty H, Westerhuis R, Pen A, Schut T. A controlled comparative study of fluphenazine and fluphenazine enanthate in acute and chronic psychotic patients. Psychiatria Neurologia Neurochirurgia 1970;73(3):165-75. [MEDLINE: 4912332]
77. Vestre ND, Hall WB, Schiele BC. A comparison of fluphenazine, triflupromazine, and phenobarbital in the treatment of chronic schizophrenic patients: a double-blind controlled study. Journal of Clinical and Experimental Psychopathology 1962;23:149-59. [MEDLINE: 67163670]
78. Watt DC. Maintenance drugs for schizophrenia. Lancet 1978;2(8098):1045-6. [MEDLINE: 79052029]
79. Wistedt B. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatrica Scandinavica 1981;64(1):65-84. [MEDLINE: 7032224]
80. Wistedt B. Neuroleptics and depression. Archives of General Psychiatry 1982;39(6):745. [MEDLINE: 6124226]
81. Wistedt B, Jorgensen A, Wiles D. A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology 1982;78(4):301-4. [MEDLINE: 83118214]
82. Wistedt B, Wiles D, Jorgensen A. A depot neuroleptic withdrawal study neurological effects. Psychopharmacology 1983;80(2):101-5. [MEDLINE: 4874164]
83. Zahn TP, Pickar D. Autonomic effects of clozapine in schizophrenia - comparison with placebo and fluphenazine. Biological Psychiatry 1993;34(1-2):3-12.
84. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences 2000;97(14):8104-9. [MEDLINE: 10884434]
85. Ahmed I, Soares K, Seifas R, Adams CE. Randomised controlled trials in Archives of General Psychiatry (1959-1995): a prevalence study. Archives of General Psychiatry 1998;55(8):754-5.
86. Altman DG, Bland JM. Detecing skewness from summary information. BMJ 1996;313:1200. [: OLZ020600]
87. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
88. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
89. Caldwell CB, Gottesman II. Schizophrenia - a high-risk factor for suicide: clues to risk reduction. Suicide and Life-Threatening Behavior 1992;22:479-93.
90. Darling HF. Fluphenazine: a preliminary study. Disease of the Nervous System 1959;20(4):167-70. [MEDLINE: 13652801]
91. Davis JM, Andriukatis S. The natural course of schizophrenia and effective maintenance drug therapy. Journal of Clincal Psychopharmacology 1986;6(1Suppl):2S-10S.
92. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
93. Dencker SJ, Lepp M, Malm U. Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiatria Scandinavica 1980;61((supp 279)):64-76.
94. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
95. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
96. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
97. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
98. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
99. Gjedde A, Wong DF. Quantification of neuroreceptors in living human brain v. endogenous neurotransmiter inhibition of haloperidol binding in psychosis. Journal of Cerebral Blood Flow Metabolism 2001;21(8):982-94. [MEDLINE: 11487734]
100. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
101. Guy U. ECDEU assessment manual for psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976.
102. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995;346(8983):1130-1.
103. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
104. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library. Chichester: John Wiley & Sons, Ltd, 2005, issue 3.
105. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
106. Holt JP, Wright ER. Preliminary results with fluphenazine (prolixin) in chronic psychotic patients. American Journal of Psychiatry 1960;117:157-9. [MEDLINE: 14402852]
107. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine Monograph Suppl. 1992;22(4):1092. [MEDLINE: 1565705]
108. Kane JM, Woerner M, Sarantakos S. Depot neuroleptics: A comparison review of standard, intermediate and low-dose regimens. Journal of Clinical Psychiatry 1986;47(suppl 5):30-3.
109. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
110. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
111. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
112. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
113. Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biological Psychiatry 1999;46(5):681-8. [MEDLINE: 10472420]
114. Lorr M. The Multidimensional Scale for Rating Psychiatric Patients. Washington D.C.: U.S.V.I, T.B, 1953:19-507.
115. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
116. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson M, Quarantelli M, et al. Reduced prefronatal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nature Neuroscience 2002;5(3):267-71. [MEDLINE: 11865311]
117. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285(12):1987-91.
118. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
119. Rust J, Golombok S. Modern Psychmetrics. London: Routledge, 1989.
120. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
121. Schulz KF, Altman DG, Moher D. For the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Annals of Internal Medicine 2010 June 1;152(11):726-32.
122. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
123. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998;317:1181-4.
124. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92. [MEDLINE: 10982317]
125. Essential Medicines. WHO Model List. 14th Edition. http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf.
126. Wikipedia (The Free Encyclopedia). http://en.wikipedia.org/wiki/Fluphenazine#Pharmacokinetics Accessed in Nov 2006.
127. Psychotropics. http://www.psychotropics.dk/.
128. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
129. Matar HE, Almerie MQ. Oral fluphenazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006352]
130. Matar HE-D, Almerie MQ, Giraldo AM, Adams CE. Oral fluphenazine versus placebo for schizophrenia: A Cochrane systematic review of 40 years of randomised controlled trials. Revista Colombiana de Psiquiatria 2007;36(1):8-17.